ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nemolizumab

Also written as “Nemolizumab”, “Nemolizumab 30 mg” and “nemolizumab (CIM331)”.

Its studies are mostly in Dermatitis, Atopic · Prurigo · Scleroderma, Systemic · Pruritus · Renal Insufficiency, Chronic, led by 4 companies.

Drug pageNemolizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 11, 201923 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Group205 open or runningphase 3since Jun 11, 2019Mar 29, 2017Dec 2026phase 2 · NCT07074977
Hoffmann-La Rocheits history only10 open or runningphase 2since Oct 31, 2013Oct 31, 2013none ahead
Maruhoits history only10 open or runningphase 2since Jan 17, 2022Jan 17, 2022none ahead
The Skin Center Dermatology Groupits history only11 open or runningphase 4since Feb 1, 2026Feb 1, 2026Jun 2027phase 4 · NCT07396168

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Galderma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 29, 2017.

  1. Jun 7, 2017Phase 2 study in Prurigo NodularisNCT03181503 · 70 enrolled · Austria, France, Germany and more
  2. Mar 29, 2019Phase 2 study in Dermatitis, AtopicNCT03921411 · 20 enrolled · United States
  3. Jun 11, 20193 phase 3 studiesNCT03985943, NCT03989349, NCT03989206
  4. Dec 17, 2019Phase 3 study in Prurigo NodularisNCT04204616 · 500 enrolled · United States, Austria, Belgium and more
  5. Apr 24, 2020Phase 2 study in Dermatitis, AtopicNCT04365387 · 242 enrolled · United States
  6. Jul 30, 20202 phase 3 studies in PrurigoNCT04501679, NCT04501666
  7. Sep 18, 2020Phase 2 study in Dermatitis, AtopicNCT04562116 · 17 enrolled · United States, Bulgaria
  8. Jun 4, 2021Phase 2 study in Dermatitis, AtopicNCT04921345 · 109 enrolled · United States, Denmark, Hungary and more
  9. Sep 13, 20213 phase 3 studiesNCT05052983, NCT05056779, NCT05075408
  10. Jun 1, 2022Phase 1 study in Dermatitis, AtopicNCT05405985 · 192 enrolled · United States
  11. Jun 24, 20252 phase 2 studiesNCT07074977, NCT07047690
  12. May 28, 2026Phase 2 study in Moderate-to-Severe Atopic DermatitisNCT07660835 · 35 planned · United States
  13. Aug 10, 2026Phase 3 study in Dermatitis, AtopicNCT07762833 · 240 planned · China
  14. Oct 16, 2026Primary completion moved from 2027-09-28 to 2027-10-28Date moved laterphase 3 · +1 months · NCT07762833

Ahead

  1. Dec 2026Primary completion: phase 2 study in Chronic Pruritus of Unknown OriginNCT07074977
  2. Oct 28, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07762833
  3. May 28, 2028Primary completion: phase 2 study in Scleroderma, SystemicNCT07047690
  4. Jul 15, 2028Primary completion: phase 2 study in Moderate-to-Severe Atopic DermatitisNCT07660835

TargetBeta

IL31RA →read by rule
“Interleukin-31 receptor subunit alpha inhibitor”ChEMBL 37, by rule

Other programs on IL31RA

ProgramCompanyFurthest phaseStudies
ABBV-313AbbViephase 11

Studies

All 20 Galderma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07762833Dermatitis, Atopic · China3RecruitingOct 28, 2027240
NCT07660835Moderate-to-Severe Atopic Dermatitis · United States2RecruitingJul 15, 202835
NCT07074977Chronic Pruritus of Unknown Origin · United States, Canada2Active, not recruitingDec 202650
NCT07047690Scleroderma, Systemic · United States, Switzerland2RecruitingMay 28, 2028162
NCT05405985Dermatitis, Atopic · United States1CompletedNov 11, 2022192
NCT05075408Renal Insufficiency, Chronic · United States, Hungary, Poland and more3CompletedJan 4, 2024258
NCT05056779Moderate-to-severe Atopic Dermatitis3WithdrawnJul 20230
NCT05052983Prurigo Nodularis · United States, Austria, France and more3CompletedSep 11, 202334
NCT04921345Dermatitis, Atopic · United States, Denmark, Hungary and more2CompletedApr 28, 2025109
NCT04562116Dermatitis, Atopic · United States, Bulgaria2CompletedJun 7, 202317
NCT04501679Prurigo · United States, Belgium, Canada and more3CompletedMar 30, 2022274
NCT04501666Prurigo · United States, Austria, Canada and more3CompletedNov 11, 2022286
NCT04365387Dermatitis, Atopic · United States2CompletedJul 7, 2023242
NCT04204616Prurigo Nodularis · United States, Austria, Belgium and more3Active, not recruitingOct 26, 2026500
NCT03989349Dermatitis, Atopic · United States, Belgium, Bulgaria and more3CompletedFeb 23, 2022787
NCT03989206Moderate-to-Severe Atopic Dermatitis · United States, Australia, Austria and more3CompletedAug 31, 20261,935
NCT03985943Dermatitis, Atopic · United States, Australia, Austria and more3CompletedDec 29, 2021941
NCT03921411Dermatitis, Atopic · United States2CompletedAug 19, 202020
NCT03181503Prurigo Nodularis · Austria, France, Germany and more2CompletedSep 26, 201870
NCT03100344Dermatitis, Atopic · United States, Australia, Canada and more2CompletedJul 19, 2018226

How it is read

Names in the registry

  • “Nemolizumab”, 20 entries
  • “Nemolizumab 30 mg”, 2 entries
  • “nemolizumab”, 2 entries
  • “nemolizumab (CIM331)”, 1 entry
  • “CD14152 Dose A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.